Literature DB >> 10632081

Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: their intestinal mucosal toxicity and absorption-enhancing mechanism of n-lauryl-beta-D-maltopyranoside.

T Uchiyama1, T Sugiyama, Y S Quan, A Kotani, N Okada, T Fujita, S Muranishi, A Yamamoto.   

Abstract

We have examined the in-vitro permeability characteristics of insulin in the presence of various absorption enhancers across rat intestinal membranes and have assessed the intestinal toxicity of the enhancers using an in-vitro Ussing chamber method. The absorption enhancing mechanism of n-lauryl-beta-D-maltopyranoside was studied also. The permeability of insulin across the intestinal membranes was low in the absence of absorption enhancers. However, the permeability was improved in the presence of enhancers such as sodium glycocholate and sodium deoxycholate in the jejunum, and sodium glycocholate, sodium deoxycholate, n-lauryl-beta-D-maltopyranoside, sodium caprate and ethylenediaminetetraacetic acid (EDTA) in the colon. Overall, the absorption enhancing effects were greater on the colonic membrane than on the jejunal membrane. The intestinal membrane toxicity of these enhancers was characterized using the release of cytosolic lactate dehydrogenase from the colonic membrane. A marked increase in the release of lactate dehydrogenase was observed in the presence of sodium deoxycholate and EDTA. The release of lactate dehydrogenase in the presence of these absorption enhancers was similar to that seen with sodium dodecyl sulphate (SDS), used as a positive control, indicating high toxicity of these enhancers to the intestinal membrane. In contrast, sodium glycocholate and sodium caprate caused minor releases of lactate dehydrogenase, similar to control levels, suggesting low toxicity. In addition, the amount of lactate dehydrogenase in the presence of n-lauryl-beta-D-maltopyranoside was much less than that seen with sodium deoxycholate, EDTA and SDS. Therefore, sodium glycocholate, sodium caprate and n-lauryl-beta-D-maltopyranoside are useful absorption enhancers due to their high absorption enhancing effects and low intestinal toxicity. To investigate the absorption enhancing mechanisms of n-lauryl-beta-D-maltopyranoside, the transepithelial electrical resistance (TEER), voltage clamp experiments and the circular dichroism spectra were studied. n-Lauryl-beta-D-maltopyranoside decreased the TEER values in a dose-dependent manner, suggesting that the enhancer may open the tight junctions of the epithelium, thereby increasing the permeability of insulin via a paracellular pathway. This speculation was supported by the findings that 20 mM n-lauryl-beta-D-maltopyranoside produced a greater increase in the paracellular flux rate than in the transcellular flux rate by the voltage clamp studies. Evaluating the circular dichroism spectra we found that insulin oligomers were not dissociated to monomers by the addition of n-lauryl-beta-D-maltopyranoside, but dissociation did occur with the addition of sodium glycocholate. Thus, the dissociation of insulin was not a major factor in the absorption enhancing effect of n-lauryl-beta-D-maltopyranoside. These findings provide basic information to select the optimal enhancer for the intestinal delivery of peptide and protein drugs including insulin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10632081     DOI: 10.1211/0022357991776976

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  19 in total

Review 1.  Waiting to inhale: noninjectable insulin, are we there yet?

Authors:  Kjeld Hermansen
Journal:  Curr Diab Rep       Date:  2004-10       Impact factor: 4.810

2.  Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels.

Authors:  Nusrat A Motlekar; Kalkunte S Srivenugopal; Mitchell S Wachtel; Bi-Botti C Youan
Journal:  J Drug Target       Date:  2005-12       Impact factor: 5.121

3.  Magnetically responsive polymeric microparticles for oral delivery of protein drugs.

Authors:  Jianjun Cheng; Benjamin A Teply; Seok Yoon Jeong; Christopher H Yim; Dennis Ho; Ines Sherifi; Sangyong Jon; Omid C Farokhzad; Ali Khademhosseini; Robert S Langer
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.200

4.  Absorption enhancement study of astragaloside IV based on its transport mechanism in caco-2 cells.

Authors:  C R Huang; G J Wang; X L Wu; H Li; H T Xie; H Lv; J G Sun
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Jan-Mar       Impact factor: 2.441

5.  Mechanistic analysis of chemical permeation enhancers for oral drug delivery.

Authors:  Kathryn Whitehead; Samir Mitragotri
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

6.  Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats.

Authors:  T Uchiyama; A Kotani; H Tatsumi; T Kishida; A Okamoto; N Okada; M Murakami; T Fujita; Y Fujiwara; Y Kiso; S Muranishi; A Yamamoto
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

7.  Modulation of gastrointestinal permeability of low-molecular-weight heparin by L-arginine: in-vivo and in-vitro evaluation.

Authors:  Nusrat Abbas Motlekar; Kalkunte Srirangachar Srivenugopal; Mitchell S Wachtel; Bi-Botti Celestin Youan
Journal:  J Pharm Pharmacol       Date:  2006-05       Impact factor: 3.765

8.  Evaluation of the Oral Bioavailability of Low Molecular Weight Heparin Formulated With Glycyrrhetinic Acid as Permeation Enhancer.

Authors:  Nusrat A Motlekar; Kalkunte S Srivenugopal; Mitchell S Wachtel; Bi-Botti C Youan
Journal:  Drug Dev Res       Date:  2006-02       Impact factor: 4.360

9.  Efficacious intestinal permeation enhancement induced by the sodium salt of 10-undecylenic acid, a medium chain fatty acid derivative.

Authors:  David J Brayden; Edwin Walsh
Journal:  AAPS J       Date:  2014-06-25       Impact factor: 4.009

10.  Chitosan as a pore former in coated beads for colon specific drug delivery of 5-ASA.

Authors:  Wycliffe S Omwancha; Rama Mallipeddi; Brenda L Valle; Steven H Neau
Journal:  Int J Pharm       Date:  2012-11-28       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.